FDA's New Pre-Approval Inspection Rules

TL;DR

FDA issued a revised Compliance Program 7346.832 on June 29, 2026, replacing the October 2022 version, effective August 10, 2026 — the operating manual investigators follow for Pre-Approval Inspections (PAIs) of NDA and ANDA manufacturing sites (FDA CP 7346.832, issued 06/29/2026).

The core change: an Integrated Quality Assessment (IQA) team now scores each facility's risk before deciding whether a PAI happens at all, and which of five Objective 1 sub-objectives get inspected if it does (RAPS, July 7, 2026).

Data integrity audits and conformance-to-application review stay mandatory on every single PAI, no exceptions, no risk-based carve-out (FDA CP 7346.832, Part IV).

Foreign inspection reports under Mutual Recognition Agreements, section 704(a)(4) records requests, and remote interactive evaluations can now substitute for or precede an on-site visit (GMP Insiders, July 10, 2026).

The preapproval program manager must enter a facility recommendation within 20 business days of an inspection closing, and always before the user fee goal date (FDA CP 7346.832, Field Reporting Requirements).

"Revised to Strengthen the Risk-Based Strategy": What FDA Actually Changed

That phrase isn't a paraphrase. It's the exact revision line printed on page 1 of Compliance Program 7346.832, dated June 29, 2026: the guide has been "revised to further strengthen the risk-based strategy to make a prompt decision on the need for inspections and promote efficient conduct of the inspections" (FDA CP 7346.832). It takes effect August 10, 2026, and it replaces a version that had been in place since October 2022.

Most compliance teams file a line like that under "process efficiency, not my problem." Wrong read. This revision changes whether an inspector shows up at your facility, and if one does, which parts of your operation get scrutinized. A clean inspection history can now earn a narrower PAI, or none. New equipment, recent quality-system changes, or prior findings pull deeper coverage in automatically. Readiness used to determine how you performed during a PAI. Now it determines whether one happens at all.

Who Decides, and On What Timeline

An Integrated Quality Assessment (IQA) team, made up of a drug substance assessor, a drug product assessor, an Office of Pharmaceutical Manufacturing Assessment (OPMA) manufacturing assessor, an inspection team lead, and a preapproval program manager (PAM), determines PAI need for every facility named in a pending application (GMP Insiders, July 10, 2026). Within 60 calendar days of an NDA or ANDA submission, OPMA must either request a PAI with a written risk-based justification through the CDER Informatics Platform, or document a facility recommendation without one.

Once an inspection closes, the clock keeps running. The inspection team lead communicates concerns to the PAM within 2 business days of closing, and the PAM must enter a final facility recommendation, approve or withhold, no later than 20 business days after close, and always before the application's user fee goal date (FDA CP 7346.832, Field Reporting Requirements).

The 8-Point Readiness Checklist

Here's what a compliance team should actually be doing before August 10, 2026, and every PAI cycle after it.

Pull your facility's own risk profile. The IQA team weighs profile-code status, compliance history, inspection history, and hazard signals, recalls, complaints, field alert reports, and MedWatch reports, when deciding whether to inspect and how deep (GMP Insiders, July 10, 2026). Know what that file already says about you before FDA does.
Rehearse the data integrity audit specifically. Objective 3 stays mandatory on every PAI regardless of risk score. Investigators are instructed to compare raw electronic and hardcopy data, chromatograms, spectrograms, analyst notebooks, against the summary data filed in your CMC section (FDA CP 7346.832).
Reconcile the filed application against the shop floor. Conformance-to-application review is also mandatory on every PAI. If your batch records, methods, or equipment have drifted from what's in the application, that gap is the review, not a footnote to it.
Map your Objective 1 sub-objective exposure. New buildings, new equipment, recent quality-system changes, and unresolved prior findings each pull additional sub-objectives into scope, sampling and testing programs, facility and equipment controls, batch release and investigation procedures (GMP Insiders, July 10, 2026). If any of those apply to you, assume the corresponding coverage is coming.
Get Stage 1 process validation defensible, not necessarily finished. A withhold recommendation won't be issued solely because Stage 2 process performance qualification is incomplete. But Stage 1 process design data has to be available and defensible, and if you claim Stage 2 is done, investigators will fully audit that claim (FDA CP 7346.832, Part V).
Prepare for a records request or remote evaluation as the actual inspection. Section 704(a)(4) requests and remote interactive evaluations can now substitute for, or precede, an on-site visit (FDA CP 7346.832). Treat a document request with the same rigor as a site visit, because it may be the only inspection you get, or the one that decides whether a bigger one follows.
Check your readiness documentation before FDA asks for it. Lack of manufacturing readiness is itself a listed ground for a withhold recommendation. If your facility isn't ready when inspection planning starts, a responsible official has to submit a written explanation and an availability date (FDA CP 7346.832, Part V).
Confirm your ICH Q12 established conditions have supporting studies on file. Where your application proposes established conditions and reporting categories, the OPMA assessor will request written coverage of the development studies behind them before the inspection starts (GMP Insiders, July 10, 2026).

FAQ

Does the revised CPG 7346.832 apply to biologics license applications?

No. Prelicense inspections and PAIs for biologics license applications follow a separate document, compliance program 7346.832M, Prelicense and Preapproval Inspections of CDER-Regulated Biological Product Manufacturers (FDA CP 7346.832, Remarks §4).

Can FDA skip an on-site PAI entirely under the new program?

Yes, where the risk assessment supports it. FDA can rely on inspection reports from trusted foreign regulators under Mutual Recognition Agreements, section 704(a)(4) records requests, or remote interactive evaluations instead of, or ahead of, an on-site visit. FDA is explicit that remote assessments alone don't satisfy the statutory inspection requirement under section 510(h), but they can still resolve the preapproval question or narrow what an on-site visit needs to cover (GMP Insiders, July 10, 2026).

If our facility has an unresolved Warning Letter, does that guarantee a PAI?

The revised program doesn't publish a strict guarantee either way, but prior findings are explicitly one of the inputs the IQA team weighs when scoring facility risk, alongside compliance history and hazard signals. Treat an open Warning Letter as a strong signal that your next application will draw deeper PAI scrutiny, not a coincidence if it does.

FDA's New Pre-Approval Inspection Rules: An 8-Point Readiness Checklist